Latest from research and the clinic.
New trial results, patient questions answered, India updates, and plain-language commentary on Lutetium therapy. Updated weekly. Reviewed by medical oncologists.
Your Prostate Cancer Just Became Hormone-Resistant: Weighing Lu-177 PSMA Against Standard Options at This Critical Turning Point
When hormone therapy stops controlling your prostate cancer, the options ahead can feel overwhelming. This guide explains how Lu-177 PSMA therapy compares to chemotherapy and other standard mCRPC treatments, using plain language and real clinical trial data.
How to Get Insurance Pre-Authorization and Financial Coverage for Lu-177 DOTATATE Before Traveling to India — Strategy for NET Patients
If you have a neuroendocrine tumor and are considering Lu-177 DOTATATE therapy in India, navigating insurance pre-authorization and financial coverage is your first critical step. This guide gives NET patients a practical, document-by-document strategy for securing coverage before they travel.
Denied Lu-177 PSMA Therapy? Understanding Eligibility Criteria and How to Get a Second Opinion from a Specialist
If you have been told you do not qualify for Lu-177 PSMA therapy, that decision may rest on scan interpretation or criteria that can be reassessed. This guide explains what eligibility really means and how a specialist second opinion may open new doors.
Planning Your Lu-177 PSMA Treatment Cycle in India: A Medical Preparation and Travel Guide for International Patients
Planning Lu-177 PSMA therapy in India requires careful medical preparation and practical travel coordination. This guide walks international patients through eligibility requirements, treatment timelines, radiation safety rules, and what to expect on each visit.
Is Lu-177 DOTATATE Worth Traveling to India For If You Live in Australia — Cost, Outcomes, and Quality Comparison for International Patients
Australian patients with GEP-NETs face limited access and high costs at home. This guide compares Lu-177 DOTATATE access, clinical outcomes, and quality of care in India versus Australia — and explains what international travel for PRRT actually involves.
My mCRPC Team Said I Should Do Chemotherapy Before Lu-177 PSMA — Should I Get a Second Opinion About Treatment Sequencing?
The FDA expanded its approval of Lu-177 PSMA therapy in March 2025 to include men with mCRPC who have not yet had chemotherapy. If your team is recommending chemo first, here is what the latest evidence says — and why a second opinion on sequencing may be one of the most important steps you take.
I'm 78 Years Old and Too Frail for Chemotherapy — Can I Still Get Lu-177 PSMA Therapy? What the Evidence Says About Age and Fitness
Being told you are too frail for chemotherapy does not automatically close the door on Lu-177 PSMA therapy. Here is what the evidence says about age, fitness, and eligibility for older men with mCRPC.
If My Neuroendocrine Tumor Is Well-Differentiated and Not Yet Metastatic, Should I Start Lu-177 DOTATATE Now or Wait Until It Progresses — What Does the Evidence Say?
If your well-differentiated neuroendocrine tumor has not yet spread, should you push for Lu-177 DOTATATE now or follow a watch-and-wait approach? Here is what the clinical evidence actually says about timing, eligibility, and what to do next.
Do I Need Lu-177 DOTATATE Right Away for My Metastatic Grade 1 Neuroendocrine Tumor — or Can My Doctors Watch and Wait?
If you have a metastatic Grade 1 neuroendocrine tumor and feel relatively well, the question of whether to start Lu-177 DOTATATE immediately or observe first is one of the most nuanced decisions in NET care. Here is what the evidence says about timing, sequencing, and what changes the calculus.
Can I Use Acupuncture, Supplements, or Alternative Therapies While on Lu-177 DOTATATE for Carcinoid Tumor? What's Safe and Evidence-Based
If you are on Lu-177 DOTATATE for a carcinoid tumor and wondering whether acupuncture, vitamins, or herbal supplements are safe, the answer is nuanced. Here is what the current evidence actually says — and why transparency with your care team is the most important step you can take.
Can I Combine Lu-177 PSMA with Checkpoint Inhibitors or Other Immunotherapies — What the Evidence Says About Dual-Therapy Options
Researchers are testing whether Lu-177 PSMA radioligand therapy and checkpoint inhibitors may work better together than either treatment alone. Here is what the early evidence shows — and what it means for patients with advanced prostate cancer today.
What Can I Eat During Lu-177 DOTATATE Treatment for My Midgut Neuroendocrine Tumor — and Can Diet Help My Treatment Work Better
Midgut neuroendocrine tumors create unique nutritional challenges — especially during Lu-177 DOTATATE treatment. This guide explains what to eat, what to avoid, and what the evidence suggests about whether diet can support how well your body responds to treatment.
How we choose what to write about
We focus on three kinds of content:
- Trial results that change practice - plain-language summaries of new evidence, with honest framing of what it does and doesn't mean
- Patient questions we hear repeatedly - taking the most common navigator-conversation questions and answering them publicly
- India updates - new centers, new approvals, new policies that affect Indian and India-bound patients
Every clinical post is reviewed by an oncologist or nuclear medicine physician before publication.
Have a specific question about your situation?
A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.
Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.